Literature DB >> 21469911

Similarity of vertigo attacks due to Meniere's disease and benign recurrent vertigo, both with and without migraine.

Krister Brantberg1, Robert W Baloh.   

Abstract

CONCLUSION: Vertigo attacks in patients with benign recurrent vertigo (BRV) cannot be distinguished from those in patients with Meniere's disease on the basis of duration, triggers or associated symptoms (other than auditory). A subset of BRV is associated with migraine.
OBJECTIVE: To investigate whether clinical features of vertigo attacks can distinguish patients with BRV from those with Meniere's disease and whether subtypes of BRV can be identified.
METHODS: A structured interview was used to analyze features in patients with BRV, i.e. those who have normal audiograms and caloric test results even though they have had recurrent vertigo (n = 63). A group of patients with definite Meniere's disease (n = 112) served as the comparison group.
RESULTS: Compared with the Meniere's disease group, patients with BRV had a female preponderance, earlier age of onset, and increased incidence of migraine headaches (IHS criteria). With regard to the vertigo attacks, duration tended to be shorter in patients with BRV but there was a large overlap in the duration of attacks between the two groups. Triggers (stress/emotional upset, fatigue, menstrual periods) and associated symptoms (imbalance, nausea and vomiting, headache, sensitivity to light) were not significantly different in the two groups.

Entities:  

Mesh:

Year:  2011        PMID: 21469911     DOI: 10.3109/00016489.2011.556661

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  17 in total

1.  Endolymphatic hydrops in patients with vestibular migraine and auditory symptoms.

Authors:  Robert Gürkov; Claudia Kantner; Michael Strupp; W Flatz; Eike Krause; Birgit Ertl-Wagner
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10       Impact factor: 2.503

2.  Tone burst electrocochleography disproves a diagnosis of Meniere's disease treated aggressively.

Authors:  J Hornibrook; J Gourley; G Vraich
Journal:  HNO       Date:  2020-05       Impact factor: 1.284

3.  [Vestibular migraine: diagnostic criteria: consensus document of the Bárány Society and the International Headache Society].

Authors:  T Lempert; J Olesen; J Furman; J Waterston; B Seemungal; J Carey; A Bisdorff; M Versino; S Evers; D Newman-Toker
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

4.  The Reliability and Validity of "Dokuz Eylül University Meniere's Disease Disability Scale".

Authors:  Başak Mutlu; Günay Kırkım; Serpil Mungan Durankaya; Selhan Gürkan; Tahsin Oğuz Başokçu; Enis Alpin Güneri
Journal:  J Int Adv Otol       Date:  2018-08       Impact factor: 1.017

Review 5.  Vestibular Migraine.

Authors:  Gülden Akdal
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

6.  Can verapamil be effective in controlling vertigo and headache attacks in vestibular migraine accompanied with Meniere's disease? A preliminary study.

Authors:  Isa Kaya; Sevinc Eraslan; Ceyda Tarhan; Cem Bilgen; Tayfun Kirazli; Figen Gokcay; Hale Karapolat; Nese Celebisoy
Journal:  J Neurol       Date:  2019-04-15       Impact factor: 4.849

Review 7.  Vestibular Migraine.

Authors:  Shin C Beh
Journal:  Curr Neurol Neurosci Rep       Date:  2022-08-31       Impact factor: 6.030

8.  Motion sensitivity and caloric responsiveness in vestibular migraine and Meniere's disease.

Authors:  Jeffrey D Sharon; Timothy E Hullar
Journal:  Laryngoscope       Date:  2014-01-15       Impact factor: 3.325

9.  A hypothetical proposal for association between migraine and Meniere's disease.

Authors:  Brooke Sarna; Mehdi Abouzari; Harrison W Lin; Hamid R Djalilian
Journal:  Med Hypotheses       Date:  2019-10-12       Impact factor: 1.538

10.  Recurrent Vestibular Symptoms Not Otherwise Specified: Clinical Characteristics Compared With Vestibular Migraine and Menière's Disease.

Authors:  Julia Dlugaiczyk; Thomas Lempert; Jose Antonio Lopez-Escamez; Roberto Teggi; Michael von Brevern; Alexandre Bisdorff
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.